Transferrin as a thermosensitizer in radiofrequency hyperthermia for cancer treatment

• Published in: Scientific reports Vol. 8; no. 1; pp. 13505 - 11
• Main Authors: Chung, Hea-Jong, Lee, Heui-Kwan, Kwon, Ki Beom, Kim, Hyeon-Jin, Hong, Seong-Tshool
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.09.2018; Nature Publishing Group; Nature Portfolio
• Subjects: 13/106; 14/5; 14/63; 59/5; 631/67/1059/153; 64/60; 692/700/565/1436/99; Blood circulation; Cancer; Cancer therapies; Fever; High temperature; Humanities and Social Sciences; Hyperthermia; multidisciplinary; Paclitaxel; Science; Science (multidisciplinary); Tissues; Transferrins; Vascularization; Xenografts
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-31232-9

One of the main characteristics of cancer tissues is poor development of neovascularization that results in a limited blood circulation. Because of this phenomenon, it is harder for cancer tissues to diffuse their elevated heat into other parts of the body. The scientific principle of radiofrequency hyperthermia relies on this quality of cancer tissues which with higher temperature becomes more apparent. Despite the obvious necessity to selectively heat the cancer tissue for radiofrequency hyperthermia, a proper thermosensitizer has not been developed until now. Here, we show that transferrin containing ferric ion could be an ideal thermosensitizer for the increased efficiency of radiofrequency hyperthermia. In our result, the ferric ion-enriched cancer tissues dramatically react with 13.56 MHz radiofrequency wave to cause cancer-selective dielectric temperature increment. The overall anticancer efficacy of a 13.56 MHz radiofrequency hyperthermia using transferrin as a thermosensitizer was much higher than the oncotherapeutic efficacy of paclitaxel, successfully eradicating cancer in a tumor-xenografted mouse experiment.